Glycogen synthase kinase-3β (GSK-3β) and Nuclear Factor Kappa-B (NF-kB) in childhood acute lymphoblastic leukemia.

dc.creatorLAYTON TOVAR, CRISTIAN FABIAN; 554062
dc.creatorMendieta Zerón, Hugo; 45175
dc.creatorCamarillo Romero, María del Socorro; 226622
dc.creatorFABILA SANCHEZ, YANKO VALENTIN; 36509
dc.creatorTejocote Romero, Isidoro;x1349058
dc.creatorLAYTON TOVAR, CRISTIAN FABIAN
dc.creatorMendieta Zerón, Hugo
dc.creatorCamarillo Romero, María del Socorro
dc.creatorFABILA SANCHEZ, YANKO VALENTIN
dc.creatorTejocote Romero, Isidoro
dc.date2020-11-05T01:10:18Z
dc.date2020-11-05T01:10:18Z
dc.date2016
dc.date.accessioned2022-10-13T00:02:15Z
dc.date.available2022-10-13T00:02:15Z
dc.identifier1899-5276
dc.identifierhttp://hdl.handle.net/20.500.11799/109383
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/4153000
dc.descriptionBackground. Acute lymphocytic leukemia (ALL) is the most common hematologic malignancy in early childhood. In children with acute lymphoblastic leukemia (ALL), the activity of glycogen synthase kinase (GSK-3β) has been associated with changes in the transcriptional activity and expression of nuclear factor kappa beta (NFKB) in the mononuclear cells of bone marrow. Objectives. The aim of the study was to determine the possible role of glycogen synthase kinase 3beta (GSK-3β) and nuclear factor kappa beta (NFKB) as prognostic variables in pediatric patients with ALL. Material and Methods. This was a descriptive, transversal, and observational study. Bone marrow and blood samples were obtained from 30 children with newly-diagnosed ALL, who were seen at the Hematology-Oncology Service, Hospital para el Niño (HPN), Toluca, Mexico, from 2014‒2015. Anthropometric variables, clinical lab results, immunophenotype and cytogenetic abnormalities were registered. GSK-3β was evaluated through immunohistochemistry, and NFKB messenger RNA (mRNA) with real-time polymerase chain reaction (qPCR). The cases of ALL were classified into two groups of risk: high and habitual. Results. Thirty patients were included in this study, with a mean age of 7.1 years (range 2‒13 years). Twenty-one were male and 9 female. Employing the morphological classification, 26 patients had type L1 ALL and the remaining 4 patients had type L2 ALL. Abnormal genes were found in 7 (23.33%) patients, ETV-RUNX1 in 3, followed by TCF3-PBX1 (two), STL1-TAL1 (one), and BCR-ABL1 (one). NFKB relative expression levels, in comparison to the GSK-3β immunohistochemistry results of the bone marrow samples, showed significant differences between positive and negative cases (p = 0.001) and between weak-positive and negative cases (p = 0.002). Conclusions. These results suggest that GSK-3β may be a prognostic biomarker in childhood ALL
dc.descriptionCiprés Grupo Médico
dc.languageeng
dc.publisherAdvances in Clinical and Experimental Medicine
dc.relation25
dc.relation6
dc.rightsopenAccess
dc.rightshttp://creativecommons.org/licenses/by-nc-nd/4.0
dc.subjectGlycogen Synthase Kinase-3β
dc.subjectNuclear Factor Kappa-B
dc.subjectChildhood
dc.subjectAcute Lymphoblastic Leukemia
dc.subjectMEDICINA Y CIENCIAS DE LA SALUD
dc.titleGlycogen synthase kinase-3β (GSK-3β) and Nuclear Factor Kappa-B (NF-kB) in childhood acute lymphoblastic leukemia.
dc.typeArtículo
dc.typearticle


Este ítem pertenece a la siguiente institución